# EDGAR Filing Document

**Accession Number:** 0001593984
**File Stem:** 0001178913-26-001486
**Filing Date:** 2026-3
**Character Count:** 9118
**Document Hash:** e966f47df097124a7dcc102f73e3ce8c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-001486.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001178913-26-001486

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Meyer Yaron
- **CENTRAL INDEX KEY:** 0002080106

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36349
- **FILM NUMBER:** 26770596

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 42 HAYARKON ST.
- **CITY:** YAVNE
- **PROVINCE COUNTRY:** L3
- **ZIP:** 8122745
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MediWound Ltd.
- **CENTRAL INDEX KEY:** 0001593984
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 42 HAYARKON STREET
- **CITY:** YAVNE
- **STATE:** L3
- **ZIP:** 8122745
- **BUSINESS PHONE:** 972779714100

**MAIL ADDRESS:**
- **STREET 1:** 42 HAYARKON STREET
- **CITY:** YAVNE
- **STATE:** L3
- **ZIP:** 8122745

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Meyer Yaron<br><sub>(Last) (First) (Middle)</sub><br>C/O MEDIWOUND LTD.<br>42 HAYARKON STREET<br><sub>(Street)</sub><br>YAVNE, ISRAEL 8122745<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>MediWound Ltd. [ MDWD ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, GC & Corp. Secretary_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary shares | 1413 | D |  |
| Ordinary shares<sup>(1)</sup> | 1200 | D |  |
| Ordinary shares<sup>(2)</sup> | 2357 | D |  |
| Ordinary shares<sup>(3)</sup> | 1750 | D |  |
| Ordinary shares<sup>(4)</sup> | 1850 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy ordinary shares) | 2022-12-31 | 2028-12-31 | Ordinary shares | 2857 | $36.05 | D |  |
| Stock Option (right to buy ordinary shares) | 2024-04-23 | 2030-04-23 | Ordinary shares | 4919 | $12.25 | D |  |
| Stock Option (right to buy ordinary shares) | 2025-03-04 | 2031-03-04 | Ordinary shares | 2769 | $37.52 | D |  |
| Stock Option (right to buy ordinary shares) | <sup>(5)</sup> | 2032-05-16 | Ordinary shares | 9230 | $14.42 | D |  |
| Stock Option (right to buy ordinary shares) | <sup>(6)</sup> | 2033-02-15 | Ordinary shares | 7200 | $13.32 | D |  |
| Stock Option (right to buy ordinary shares) | <sup>(7)</sup> | 2034-02-26 | Ordinary shares | 18855 | $12.729 | D |  |
| Stock Option (right to buy ordinary shares) | <sup>(8)</sup> | 2035-02-11 | Ordinary shares | 14000 | $18.54 | D |  |
| Stock Option (right to buy ordinary shares) | <sup>(9)</sup> | 2036-03-04 | Ordinary shares | 15000 | $17.60 | D |  |

---

### Footnotes:

(1) The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(2) The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(3) The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(4) The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(5) The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(6) The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(7) The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(8) The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

(9) The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

**Signature:** /s/ Yaron Meyer  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**